Enovis (ENOV) Competitors $25.74 -1.06 (-3.96%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$25.74 0.00 (0.00%) As of 08/1/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENOV vs. DOV, ITT, GKOS, BLCO, SLNO, IRTC, INSP, TMDX, NVST, and PRCTShould you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Dover (DOV), ITT (ITT), Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), Inspire Medical Systems (INSP), TransMedics Group (TMDX), Envista (NVST), and PROCEPT BioRobotics (PRCT). Enovis vs. Its Competitors Dover ITT Glaukos Bausch + Lomb Soleno Therapeutics iRhythm Technologies Inspire Medical Systems TransMedics Group Envista PROCEPT BioRobotics Enovis (NYSE:ENOV) and Dover (NYSE:DOV) are related companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk. Do insiders and institutionals believe in ENOV or DOV? 98.5% of Enovis shares are owned by institutional investors. Comparatively, 84.5% of Dover shares are owned by institutional investors. 2.7% of Enovis shares are owned by company insiders. Comparatively, 1.3% of Dover shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to ENOV or DOV? In the previous week, Dover had 50 more articles in the media than Enovis. MarketBeat recorded 54 mentions for Dover and 4 mentions for Enovis. Enovis' average media sentiment score of 0.94 beat Dover's score of 0.45 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dover 18 Very Positive mention(s) 11 Positive mention(s) 15 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Is ENOV or DOV more profitable? Dover has a net margin of 29.29% compared to Enovis' net margin of -37.65%. Dover's return on equity of 18.19% beat Enovis' return on equity.Company Net Margins Return on Equity Return on Assets Enovis-37.65% 5.99% 3.44% Dover 29.29%18.19%9.86% Which has higher earnings and valuation, ENOV or DOV? Dover has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Dover, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnovis$2.11B0.70-$825.49M-$13.95-1.85Dover$7.75B3.10$2.70B$16.5810.55 Which has more volatility & risk, ENOV or DOV? Enovis has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Dover has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Do analysts recommend ENOV or DOV? Enovis currently has a consensus target price of $55.60, indicating a potential upside of 116.01%. Dover has a consensus target price of $213.92, indicating a potential upside of 22.26%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Dover.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Dover 0 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.58 SummaryDover beats Enovis on 10 of the 16 factors compared between the two stocks. Get Enovis News Delivered to You Automatically Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENOV vs. The Competition Export to ExcelMetricEnovisMEDICAL INFO SYS IndustryMedical SectorNYSE ExchangeMarket Cap$1.53B$2.04B$5.47B$20.69BDividend YieldN/AN/A4.73%3.67%P/E Ratio-1.8533.7928.6729.07Price / Sales0.7028.85422.5466.49Price / Cash1.3956.2135.4522.84Price / Book0.578.978.274.43Net Income-$825.49M-$62.31M$3.24B$994.22M7 Day Performance-6.51%-8.15%-3.64%-3.35%1 Month Performance-22.97%1.83%4.39%-2.06%1 Year Performance-43.32%21.01%25.97%10.15% Enovis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENOVEnovis3.1915 of 5 stars$25.74-4.0%$55.60+116.0%-44.7%$1.53B$2.11B-1.857,367Upcoming EarningsDOVDover4.7758 of 5 stars$184.91-0.9%$213.92+15.7%-2.3%$25.57B$7.75B11.1524,000Trending NewsAnalyst RevisionITTITT4.2159 of 5 stars$162.38+0.5%$173.25+6.7%+17.8%$12.71B$3.63B25.8211,700Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastGap DownGKOSGlaukos3.9692 of 5 stars$94.80+0.5%$134.67+42.1%-26.6%$5.39B$383.48M-40.00780Trending NewsEarnings ReportAnalyst ForecastBLCOBausch + Lomb2.7085 of 5 stars$14.47+1.0%$15.45+6.8%-19.8%$5.07B$4.79B-14.0513,500News CoverageEarnings ReportAnalyst ForecastSLNOSoleno Therapeutics4.2762 of 5 stars$85.25-1.4%$108.70+27.5%+74.8%$4.36BN/A-18.4530Positive NewsUpcoming EarningsIRTCiRhythm Technologies1.7857 of 5 stars$137.11+2.2%$137.30+0.1%+95.9%$4.28B$591.84M-43.672,000Trending NewsEarnings ReportAnalyst ForecastGap UpINSPInspire Medical Systems4.7194 of 5 stars$130.72+1.4%$208.55+59.5%-13.1%$3.80B$802.80M59.381,246Positive NewsUpcoming EarningsTMDXTransMedics Group2.4919 of 5 stars$105.24-2.7%$129.88+23.4%-20.4%$3.66B$441.54M79.50210Trending NewsEarnings ReportAnalyst ForecastNVSTEnvista3.5735 of 5 stars$20.73-0.3%$20.23-2.4%+22.7%$3.53B$2.51B-3.1712,300Trending NewsEarnings ReportAnalyst ForecastPRCTPROCEPT BioRobotics2.6459 of 5 stars$54.08-2.9%$84.13+55.6%-19.4%$3.08B$224.50M0.00430Upcoming Earnings Related Companies and Tools Related Companies Dover Competitors ITT Competitors Glaukos Competitors Bausch + Lomb Competitors Soleno Therapeutics Competitors iRhythm Technologies Competitors Inspire Medical Systems Competitors TransMedics Group Competitors Envista Competitors PROCEPT BioRobotics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ENOV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENOV Stock Alerts